Vinorelbine tartrate inj
Products billed under this code include Vinorelbine Tartrate.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vinorelbine Tartrate.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vinorelbine Tartrate | Sagent Pharmaceuticals | 25021-0204-01 | 1 | $4.148 |
| Vinorelbine Tartrate | Sagent Pharmaceuticals | 25021-0204-05 | 5 | $20.74 |
| Vinorelbine Tartrate | Actavis Pharma, Inc. | 45963-0607-55 | 1 | $4.148 |
| Vinorelbine Tartrate | Actavis Pharma, Inc. | 45963-0607-56 | 5 | $20.74 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $4.148 | −$0.142 | 10 MG | Vinorelbine tartrate inj | v1, posted September 17, 2026 |
| 3Q26 | $4.29 | −$0.684 | 10 MG | Vinorelbine tartrate inj | v1, posted September 15, 2026 |
| 2Q26 | $4.974 | −$0.466 | 10 MG | Vinorelbine tartrate inj | v1, posted September 15, 2026 |
| 1Q26 | $5.44 | −$2.242 | 10 MG | Vinorelbine tartrate inj | v1, posted September 15, 2026 |
| 4Q25 | $7.682 | +$5.726 | 10 MG | Vinorelbine tartrate inj | v1, posted September 8, 2026 |
| 3Q25 | $1.956 | −$4.63 | 10 MG | Vinorelbine tartrate inj | v1, posted March 10, 2026 |
| 2Q25 | $6.586 | +$0.083 | 10 MG | Vinorelbine tartrate inj | v1, posted March 10, 2026 |
| 1Q25 | $6.503 | −$1.09 | 10 MG | Vinorelbine tartrate inj | v1, posted December 19, 2025 |
| 4Q24 | $7.593 | −$0.605 | 10 MG | Vinorelbine tartrate inj | v1, posted June 11, 2025 |
| 3Q24 | $8.198 | −$0.301 | 10 MG | Vinorelbine tartrate inj | v1, posted June 11, 2025 |
| 2Q24 | $8.499 | +$1.083 | 10 MG | Vinorelbine tartrate inj | v1, posted March 11, 2025 |
| 1Q24 | $7.416 | −$0.69 | 10 MG | Vinorelbine tartrate inj | v1, posted December 19, 2024 |
| 4Q23 | $8.106 | −$0.162 | 10 MG | Vinorelbine tartrate inj | v1, posted October 10, 2024 |
| 3Q23 | $8.268 | +$0.821 | 10 MG | Vinorelbine tartrate inj | v1, posted June 5, 2024 |
| 2Q23 | $7.447 | −$1.804 | 10 MG | Vinorelbine tartrate inj | v1, posted February 23, 2024 |
| 1Q23 | $9.251 | −$0.02 | 10 MG | Vinorelbine tartrate inj | v1, posted December 6, 2023 |
| 4Q22 | $9.271 | −$2.126 | 10 MG | Vinorelbine tartrate inj | v1, posted June 22, 2023 |
| 3Q22 | $11.397 | +$0.394 | 10 MG | Vinorelbine tartrate inj | v1, posted June 9, 2023 |
| 2Q22 | $11.003 | +$2.379 | 10 MG | Vinorelbine tartrate inj | v1, posted December 14, 2022 |
| 1Q22 | $8.624 | −$1.388 | 10 MG | Vinorelbine tartrate inj | v1, posted June 8, 2022 |
| 4Q21 | $10.012 | +$0.204 | 10 MG | Vinorelbine tartrate inj | v1, posted June 2, 2022 |
| 3Q21 | $9.808 | −$0.94 | 10 MG | Vinorelbine tartrate inj | v1, posted June 2, 2022 |
| 2Q21 | $10.748 | +$1.204 | 10 MG | Vinorelbine tartrate inj | v1, posted March 1, 2022 |
| 1Q21 | $9.544 | – | 10 MG | Vinorelbine tartrate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.